slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 71,341-71,370
Pages 3,679
Rows per page 30
Component
71,341-71,370 of 110,355
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citrate-free formulation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
29
The slide uses qualitative expert feedback to support quantitative preference share data.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
42
The slide uses a timeline-based process diagram to illustrate the clinical trial strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
45
The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
05
Includes footnotes regarding arbitration and product definitions.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
06
The table includes a blue box highlighting the Q2 2023 column. Footnotes explain the impact of an arbitration settlement on Manufacturing & Royalty Revenue.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
09
The chart illustrates revenue diversification across four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
10
The chart displays both weekly data and a 4-week rolling average.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
12
The chart includes a vertical dashed line separating historical data from the most recent quarter.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
13
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
17
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Closing Ask1 hit
06
The slide uses a split-screen layout to contrast established proof-of-concept (left) with future development plans (right).argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · RoadmapLoop · Maturity Curve1 hit
03
The slide uses a list-based layout to present three key clinical findings.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
06
The slide uses a spiral/funnel-like diagram to illustrate the compounding nature of patient challenges.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
The slide highlights efficacy across different patient subsets and mentions specific clinical metrics (INCAT, I-RODS, grip strength).argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide presents clinical trial safety data for VYVGART Hytrulo.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
13
Uses a 'before-after' framing to contrast legacy treatments (IVIg, Steroids, PLEX) with the new product's benefits.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit